Media
Long Shortz with Racura Oncology: Understanding the mechanism of action that could transform cancer therapy
Racura Oncology CEO Dr Daniel Tillett spoke to Stockhead’s Tylah Tully to discuss the groundbreaking discovery of the primary mechanism of action of their lead drug. Dr Tillett explains how understanding the drug’s mechanism increases the probability of clinical success, allowing Racura to identify the cancer types most likely to respond, develop predictive biomarkers, and design…
News.com.au: ASX health stocks rise; Racura Oncology enjoys big week with lead drug discovery
Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector and selects Racura Oncology as his ‘Powerplay’ stock pick of the week. Read the full article here.
Proactive: Inside Biotech – Racura Oncology’s G4-DNA discovery sharpens clinical story
Racura Oncology has uncovered a fresh chapter in its lead cancer program, identifying a novel mechanism of action for its (E,E)-bisantrene candidate. New data shows the compound binds to G4-DNA and RNA structures — genetic “switches” that regulate cancer-driving genes like MYC — setting it apart from doxorubicin-like chemotherapies that remain the backbone of treatment…
Long Shortz with Racura Oncology: Investor insight into Racura’s patent breakthrough
Racura Oncology CEO Dr Daniel Tillett spoke to Stockhead’s Tylah Tully about the company’s major scientific discovery, which has enabled a new composition of matter patent application for the (E,E)-bisantrene compound. Dr Tillett explains why composition of matter patents are considered the gold standard in biotech IP, critical for securing future licensing and acquisition interest from…
Proactive: Racura Oncology activates Hong Kong trial site
Racura Oncology CEO Dr Daniel Tillett spoke with Proactive about the activation of the company’s first clinical site in Hong Kong for its Phase 1 RC220 trial in advanced solid tumours. Located at Queen Mary Hospital, this marks the start of patient enrolment in the region, with screening underway and the first patient expected to…
Inside Racura: Introducing Dr Jose Iglesias, Chief Medical Officer at Racura Oncology
We are pleased to share another instalment of our “Inside Racura” video interview series, introducing Chief Medical Officer Dr Jose Iglesias, who joined the Racura Oncology team in May 2025. Dr Iglesias shares what first attracted him to the field of oncology and walks us through his distinguished 36-year career as a pharmaceutical executive. He…
Stockhead: Racura Oncology opens Hong Kong site in “cautious” trial rollout
Stockhead‘s Tim Boreham has reported on Racura Oncology announcing the site activation of Queen Mary Hospital in Hong Kong, enabling the commencement of patient recruitment for Phase 1 clinical trial of RC220 in combination with doxorubicin in advanced solid tumour patients. The company hopes that as well as attacking the tumours, RC220 will protect the…
Samso: Who is Racura Oncology (ASX: RAC)? DYOR on Anti-Cancer Innovation and Heart Protection
Samso’s Noel Ong has compiled the key highlights of Racura Oncology in this note, and outlined the upcoming inflection points for the company. In his analysis, Mr Ong writes: “Most of us have known someone who is in the predicament of being a patient of some form of cancer, so the path to finding a…
Racura Oncology announces the publication of bisantrene clinical trial
Racura Oncology has announced the results of the Phase 2 clinical trial of RC110 bisantrene for relapsed or refractory acute myeloid leukaemia (AML) has been published in the peer-reviewed British Journal of Haematology, as reported by Biotech Dispatch. Read the full article here.
